Zhi-Guang Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhi-Guang Fu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Huan-Huan Wang
2 shared publicationsLi Wen
2 shared publicationsLi-Sheng Zhao
2 shared publications- Wei Li
Beijing National Laboratory for Molecular Sciences, CAS Key Laboratory of Colloid, Interface and Chemical Thermodynamics, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
2 shared publications Yun-Xia Li
2 shared publications- Dongshu Chang1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 8323-8330
Analysis of efficacy and safety of intensity-modulated radiotherapy with “Target-Ring” strategy for stage IVA large-volume thymoma and thymic carcinoma: a single-center study
Background: Thymic tumors at stage IVA are characterized by local invasion into adjacent structures (e.g., pericardium, great vessels) and/or regional lymph node metastasis, with unresectable large-volume tumors posing unique therapeutic challenges due to their proximity to critical thoracic organs and potential for high tumor burden. Additionally, previous studies have shown that conventional radiotherapy for advanced thymic malignancies may be limited by dose constraints to normal tissues, highlighting the need to assess the role of intensity-modulated radiotherapy (IMRT) in optimizing therapeutic ratios. This study aimed to evaluate the efficacy and safety of IMRT in treating unresectable large-volume thymic tumors at stage IVA. Methods: A retrospective analysis was conducted on 13 patients with unresectable large-volume stage IVA thymic tumors treated between January 2010 and June 2018. All patients received radical IMRT using the “Target-Ring” dose escalation strategy, with prescribed doses of 50 Gy to the planning target volume (PTV), 60 Gy to the clinical target volume (CTV), and 70 Gy to the gross tumor volume (GTV) delivered in 15–20 fractions. Outcomes including objective response rate (ORR), disease control rate (DCR), local progression-free survival (LPFS), overall survival (OS), and adverse reactions were analyzed. Results: The median follow-up was 82 months (range, 13–145 months). The ORR was 84.6% (11/13), and the DCR was 100% (13/13). The 1-, 3-, 5-, and 8-year OS rates were 100%, 69.2%, 61.5%, and 39.6%, respectively, while the corresponding LPFS rates were 100%, 69.2%, 59.3%, and 37.1%. Only one patient experienced grade 3 hematologic toxicity; no grade ≥3 non-hematologic toxicities were observed. Seven patients died of cancer-related progression. Conclusions: IMRT with the “Target-Ring” strategy demonstrates favorable efficacy and safety for unresectable large-volume stage IVA thymic tumors, offering a viable non-surgical treatment option.
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 8323-8330
Open AccessAnalysis of efficacy and safety of intensity-modulated radiotherapy with “Target-Ring” strategy for stage IVA large-volume thymoma and thymic carcinoma: a single-center study
Background: Thymic tumors at stage IVA are characterized by local invasion into adjacent structures (e.g., pericardium, great vessels) and/or regional lymph node metastasis, with unresectable large-volume tumors posing unique therapeutic challenges due to their proximity to critical thoracic organs and potential for high tumor burden. Additionally, previous studies have shown that conventional radiotherapy for advanced thymic malignancies may be limited by dose constraints to normal tissues, highlighting the need to assess the role of intensity-modulated radiotherapy (IMRT) in optimizing therapeutic ratios. This study aimed to evaluate the efficacy and safety of IMRT in treating unresectable large-volume thymic tumors at stage IVA. Methods: A retrospective analysis was conducted on 13 patients with unresectable large-volume stage IVA thymic tumors treated between January 2010 and June 2018. All patients received radical IMRT using the “Target-Ring” dose escalation strategy, with prescribed doses of 50 Gy to the planning target volume (PTV), 60 Gy to the clinical target volume (CTV), and 70 Gy to the gross tumor volume (GTV) delivered in 15–20 fractions. Outcomes including objective response rate (ORR), disease control rate (DCR), local progression-free survival (LPFS), overall survival (OS), and adverse reactions were analyzed. Results: The median follow-up was 82 months (range, 13–145 months). The ORR was 84.6% (11/13), and the DCR was 100% (13/13). The 1-, 3-, 5-, and 8-year OS rates were 100%, 69.2%, 61.5%, and 39.6%, respectively, while the corresponding LPFS rates were 100%, 69.2%, 59.3%, and 37.1%. Only one patient experienced grade 3 hematologic toxicity; no grade ≥3 non-hematologic toxicities were observed. Seven patients died of cancer-related progression. Conclusions: IMRT with the “Target-Ring” strategy demonstrates favorable efficacy and safety for unresectable large-volume stage IVA thymic tumors, offering a viable non-surgical treatment option.
- Open Access
- 1 June 2019
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 14, 4429-4430
The synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma [Corrigendum]
The synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma [Corrigendum] Wang H, Fu Z, Li W, et al. Int J Nanomedicine.2019;14:623–638.Errors were found in several images for Figure 5F, 5G, 6A and 6B. The authors have advised that mistakes were made during the process of organizing the images. A lot of images were captured following immunostaining and due to the similarity of these images, several of the same images were incorrectly selected. The authors and the editor have confirmed that the correction of the images has no significant impact on the conclusions of the study. Read the original article
- 1 June 2019
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 14, 4429-4430
Open AccessThe synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma [Corrigendum]
The synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma [Corrigendum] Wang H, Fu Z, Li W, et al. Int J Nanomedicine.2019;14:623–638.Errors were found in several images for Figure 5F, 5G, 6A and 6B. The authors have advised that mistakes were made during the process of organizing the images. A lot of images were captured following immunostaining and due to the similarity of these images, several of the same images were incorrectly selected. The authors and the editor have confirmed that the correction of the images has no significant impact on the conclusions of the study. Read the original article
- Open Access
- 1 January 2019
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 14, 623-638
The synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma
The synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma Huan-huan Wang,1,* Zhi-guang Fu,1,* Wei Li,2 Yun-xia Li,1 Li-sheng Zhao,1 Li Wen,1 Jian-jun Zhang,2 Ning Wen1 1Department of Stomatology, Chinese PLA General Hospital, Beijing 100853, China; 2College of Chemical Engineering, Beijing University of Chemical Technology, Beijing 100029, China *These authors contributed equally to this work Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies, with high rates of mortality and morbidity worldwide. Owing to the special anatomical location of this tumor, an effective, minimally invasive treatment with low systemic toxicity is highly desirable. Hydrogels have shown great potential for tumor-targeting therapy, with excellent performance. However, there have been few reports on co-loading photosensitizers and chemotherapeutic drugs into hydrogels. In this study, we synthesized a nano doxorubicin-indocyanine green matrix metalloproteinase (MMP)-responsive hydrogel (denoted as NDIMH), combining chemotherapy and phototherapy, to achieve superior antitumor efficacy.Methods: First, NDIMH was synthesized and characterized by scanning electron microscopy and drug-release assays. Second, the photosensitivity properties and antitumor efficiency of this drug delivery system were studied in vivo and in vitro. Last, the imaging and biodistribution of NDIMH were monitored using the Maestro EX in vivo imaging system.Results: The nanodrugs loaded into the smart hydrogel exhibited uniform size distribution, excellent size stability, and a sustained release in the presence of MMP-2. NDIMH showed ideal photosensitivity characteristics under light. NDIMH with 808 nm near-infrared (NIR) irradiation effectively inhibited the viability, invasion, and metastasis of SCC-15 in vitro. After intratumoral injection of NDIMH with 808 nm NIR illumination, the hydrogels exhibited favorable synergistic antitumor efficacy and acceptable biosafety. Additionally, fluorescence imaging showed that NDIMH could significantly improve the retention of nanodrugs at the tumor site.Conclusion: The intratumoral injection of NDIMH with 808 nm NIR irradiation could be a promising chemophototherapy alternative for HNSCC. Keywords: hydrogel, MMP-responsive, doxorubicin, indocyanine green, chemophototherapy
- 1 January 2019
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 14, 623-638
Open AccessThe synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma
The synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma Huan-huan Wang,1,* Zhi-guang Fu,1,* Wei Li,2 Yun-xia Li,1 Li-sheng Zhao,1 Li Wen,1 Jian-jun Zhang,2 Ning Wen1 1Department of Stomatology, Chinese PLA General Hospital, Beijing 100853, China; 2College of Chemical Engineering, Beijing University of Chemical Technology, Beijing 100029, China *These authors contributed equally to this work Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies, with high rates of mortality and morbidity worldwide. Owing to the special anatomical location of this tumor, an effective, minimally invasive treatment with low systemic toxicity is highly desirable. Hydrogels have shown great potential for tumor-targeting therapy, with excellent performance. However, there have been few reports on co-loading photosensitizers and chemotherapeutic drugs into hydrogels. In this study, we synthesized a nano doxorubicin-indocyanine green matrix metalloproteinase (MMP)-responsive hydrogel (denoted as NDIMH), combining chemotherapy and phototherapy, to achieve superior antitumor efficacy.Methods: First, NDIMH was synthesized and characterized by scanning electron microscopy and drug-release assays. Second, the photosensitivity properties and antitumor efficiency of this drug delivery system were studied in vivo and in vitro. Last, the imaging and biodistribution of NDIMH were monitored using the Maestro EX in vivo imaging system.Results: The nanodrugs loaded into the smart hydrogel exhibited uniform size distribution, excellent size stability, and a sustained release in the presence of MMP-2. NDIMH showed ideal photosensitivity characteristics under light. NDIMH with 808 nm near-infrared (NIR) irradiation effectively inhibited the viability, invasion, and metastasis of SCC-15 in vitro. After intratumoral injection of NDIMH with 808 nm NIR illumination, the hydrogels exhibited favorable synergistic antitumor efficacy and acceptable biosafety. Additionally, fluorescence imaging showed that NDIMH could significantly improve the retention of nanodrugs at the tumor site.Conclusion: The intratumoral injection of NDIMH with 808 nm NIR irradiation could be a promising chemophototherapy alternative for HNSCC. Keywords: hydrogel, MMP-responsive, doxorubicin, indocyanine green, chemophototherapy